Product Development

Back to School 2020: The imperative of COVID-19 — biopharma’s once-in-a-generation chance for change 

BioCentury’s 28th Annual Back to School calls on biopharma to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis.

BioCentury calls on industry to convert its COVID response to a new era of efficient drug development and address the urgent healthcare chasms exposed by the crisis

Biopharmas must address the reality of racial disparities in health outcomes exposed by COVID-19 

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset.

COVID-19 shows why biopharmas need to build racial equity into their drug development mindset

Having touched the third rail of data sharing in the pandemic, drug developers should hold on tight

COVID-19 has lit a path to greater data sharing.

COVID-19 has lit a path to greater data sharing

Master protocols should not be a one-off phenomenon confined to COVID-19

COVID-19 gives a master lesson in platform trials.

COVID-19 gives a master lesson in platform trials

Governments must work alongside industry to fill the cracks exposed by COVID-19 before the next, inevitable, pandemic

Public sector leaders must step forward to prepare for future pandemics by improving surveillance, investing in countermeasures R&D, creating markets for antibiotics, and building surge capacity for manufacturing and diagnostics.

When next crisis hits, the world should be able to turn to a stockpile of countermeasures and an efficient system for manufacturing, distributing them

Letter from the Editor: Back to School 2020

Back to School this year carries a unique irony, given that many students aren’t going back to school in any normal format. Since its launch in 1993, Back to School has been published at Labor


<div class="articleContainer"></div>
<div class="articleWrapper">
<div class="articleContent">
<h1 class="text title" doc-editable="text" data-component-id="doc-1ef7l320d0">Master protocols should not be a one-off phenomenon confined to COVID-19</h1><h2 class="title-bottom" doc-editable="title" data-component-id="doc-1ef7l34r60">COVID-19 gives&#xa0;a master lesson in platform trials</h2><div class="byline ng-tns-c17-4 ng-star-inserted" data-component-id="doc-1ef7l3fol0">
    <span class="ng-tns-c17-4" doc-editable="text">By C. Simone Fishburn, editor in chief, and steve usdin, washington editor</span>
</div><div class="date" data-component-id="doc-1ef7l3l440">
  <span class="byline" doc-editable="text"></span>
</div></div></div>


This is the fourth article in&#xa0;BioCentury&#x2019;s 28th Annual Back to School package. In the opening piece, BioCentury called on biopharma to convert ...

!function(e,i,n,s){var t="InfogramEmbeds",d=e.getElementsByTagName("script")[0];if(window[t]&&window[t].initialized)window[t].process&&window[t].process();else if(!e.getElementById(n)){var o=e.createElement("script");o.async=1,o.id=n,o.src="https://e.infogram.com/js/dist/embed-loader-min.js",d.parentNode.insertBefore(o,d)}}(document,0,"infogram-async");

Featured Analysis

Articles by Category

Current Editions

Data Graphics

Distillery: Disruptive Innovation

Distillery

Hot Topics

Podcasts & Webcasts

Special Reports & Presentations

White Papers

Analysis

BCIQ

Company Profiles

Product Profiles

Target Profiles

Financial Dashboards

BCIQ Data

All Events

Bio€quity Europe

BioCentury Grand Rounds 2024

BioCentury Grand Rounds

The BioCentury-BayHelix China Healthcare Summit

BioCentury-BayHelix China Healthcare Summit

The BioCentury Show

Webinars - Upcoming & On-Demand

Events

My Workspace

Company Overview

Management

Analysts & Research Team

Scientific Advisory Board

About BioCentury

Contact Us

Forgot Password

Request a Trial

Request a Subscription

Advertising - Sponsorship Inquiry

Media Kit

Request BioCentury's BCIQ Brochure

Customer Resource Center

Career Opportunities

Contact

Home